Financial Performance - The group recorded revenue of approximately SGD 6.3 million for the six months ended June 30, 2019, an increase of about 13.1% compared to SGD 5.5 million for the same period in 2018[9] - Gross profit for the period remained stable at SGD 3.9 million, consistent with the previous year[10] - The group achieved a net profit after tax of approximately SGD 0.6 million, a significant turnaround from a net loss of SGD 1.5 million in the same period last year, primarily due to a one-time non-recurring listing expense of approximately SGD 2.5 million incurred in the prior year[10] - Total revenue for the six months ended June 30, 2019, was SGD 6,250,853, an increase of 14.5% from SGD 5,457,229 in the same period of 2018[42] - Treatment services revenue reached SGD 3,613,779, up 9.8% from SGD 3,292,098 in 2018[42] - Medical examination services revenue increased by 25.8% to SGD 2,020,776 from SGD 1,606,447 in 2018[42] - The company reported a profit attributable to owners of SGD 556,884 for the six months ended June 30, 2019, compared to a loss of SGD 1,515,956 in the same period of 2018[46] - Basic earnings per share for the period was SGD 0.12, compared to a loss per share in the previous year[46] Assets and Liabilities - Total assets increased to SGD 15.8 million as of June 30, 2019, compared to SGD 14.2 million as of December 31, 2018[15] - Cash and cash equivalents rose to SGD 13.5 million from SGD 12.4 million at the end of 2018[15] - Trade receivables increased significantly to SGD 127,773 from SGD 55,787 in the previous year[15] - Total equity increased to SGD 13.1 million as of June 30, 2019, compared to SGD 12.6 million at the end of 2018[16] - The group reported total liabilities of SGD 2.7 million, up from SGD 1.5 million at the end of 2018[16] - Trade payables rose significantly to SGD 1,002,955 as of June 30, 2019, compared to SGD 388,119 at the end of 2018[57] - The company reported accrued operating expenses of SGD 658,295 as of June 30, 2019, up from SGD 556,914 at the end of 2018[58] Cash Flow and Capital Management - The company reported a net cash inflow from operating activities of SGD 1,436,291 for the six months ended June 30, 2019, compared to a cash outflow of SGD 1,021,717 in the same period of 2018[21] - Cash and cash equivalents as of June 30, 2019, totaled SGD 13,526,026, an increase from SGD 12,370,343 at the end of 2018[54] - The company has no bank borrowings as of June 30, 2019, consistent with the previous year[81] - The company’s retained earnings as of June 30, 2019, stood at SGD 1,104,685, reflecting an increase from SGD 547,801 at the beginning of the year[18] - The company’s capital management objective is to ensure the group can continue as a going concern while providing returns to shareholders[36] Corporate Governance and Compliance - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited condensed consolidated financial statements and found them compliant with applicable accounting standards[121] - The company is committed to maintaining high standards of corporate governance and has adopted all applicable code provisions of the GEM Listing Rules[115] - The company has established an audit committee to oversee financial reporting and risk management processes[121] - No directors or controlling shareholders have interests in any competing businesses during the reporting period[114] - The company has complied with the GEM Listing Rules regarding securities trading by directors[116] Future Plans and Investments - The company is focused on maintaining operational efficiency and exploring new market opportunities to drive future growth[10] - The net proceeds from the IPO of approximately SGD 9.1 million will be used for future expansion and business growth in Singapore[69] - The company operates seven DTAP centers and two SA centers, with plans to open another center in Bukit Timah[68] - The company has plans to open a new DTAP treatment center in the northeastern part of Singapore, postponed to the first half of 2021 due to space availability[102] - The company spent SGD 241,000 on renovations for three new DTAP treatment centers during the period[95] - The company allocated SGD 63,000 for upgrading its information technology infrastructure and systems as of June 30, 2019[99] Risks and Contingencies - The company has not faced any major foreign exchange risks as all transactions are conducted in Singapore dollars[89] - The company has not utilized any hedging contracts for speculative activities during the period[90] - There are no significant contingent liabilities reported as of June 30, 2019[87] - There are no significant events affecting the company reported after June 30, 2019[93]
REPUBLIC HC(08357) - 2019 - 中期财报